Apyx Medical (NASDAQ: APYX) director awarded 450,000 restricted stock units

Rhea-AI Filing Summary

Vizirgianakis Stavros G. reported acquisition or exercise transactions in this Form 4 filing.

Apyx Medical Corp director Stavros G. Vizirgianakis received a grant of 450,000 restricted stock units (RSUs). The award was granted at no cash cost per unit and is compensation rather than an open-market purchase.

According to the vesting schedule, 150,000 RSUs vest on June 11, 2026, 150,000 begin vesting on the first anniversary of that date and vest ratably over the following twelve months, and the remaining 150,000 follow the same ratable schedule starting on the second anniversary. After this grant, Vizirgianakis directly holds 2,196,191 shares or share-equivalents reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vizirgianakis Stavros G.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	450,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,196,191 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 450,000 units Immediate vesting tranche: 150,000 units First anniversary vesting: 150,000 units +3 more

6 metrics

RSUs granted 450,000 units Restricted stock units awarded to director on June 11, 2026

Immediate vesting tranche 150,000 units RSUs vesting on June 11, 2026

First anniversary vesting 150,000 units RSUs vesting ratably over 12 months starting first anniversary of grant date

Second anniversary vesting 150,000 units RSUs vesting ratably over 12 months starting second anniversary of grant date

Post-grant holdings 2,196,191 shares Total direct holdings following reported transaction

Grant price $0.00 per unit Stated transaction price for RSU award

Key Terms

Restricted Stock Units, vest ratably, award agreement

3 terms

Restricted Stock Units financial

"The restricted stock units vest as follows: (i) 150,000 restricted stock units vest immediately..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest ratably financial

"150,000 restricted stock units will commence vesting on the first anniversary ... and will vest ratably over the twelve (12) month period"

award agreement financial

"subject to the Reporting Person's continued service ... and the terms and conditions of the applicable award agreement"

An award agreement is a legal contract that spells out the terms of a pay or equity grant—such as stock options, restricted shares, or cash bonuses—given to an employee, director or consultant. It describes what is being granted, any conditions for keeping it (for example, earning it over time or meeting performance targets), and what happens if the person leaves or breaks rules. Investors care because these agreements affect company costs, potential share dilution and how executives are motivated and rewarded.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vizirgianakis Stavros G.

(Last) (First) (Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER FLORIDA 33760

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Restricted Stock Units	06/11/2026		A(1)		450,000	A	$0	2,196,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest as follows: (i) 150,000 restricted stock units vest immediately on June 11, 2026 (the "Grant Date"); (ii) 150,000 restricted stock units will commence vesting on the first anniversary of the Grant Date and will vest ratably over the twelve (12) month period beginning on such date; and (iii) 150,000 restricted stock units will commence vesting on the second anniversary of the Grant Date and will vest ratably over the twelve (12) month period beginning on such date, in each case subject to the Reporting Person's continued service through each applicable vesting date and the terms and conditions of the applicable award agreement.

	/s/ Stavros G. Vizirgianakis	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apyx Medical (APYX) disclose for Stavros G. Vizirgianakis?

Apyx Medical disclosed that director Stavros G. Vizirgianakis received a grant of 450,000 restricted stock units. The RSUs were awarded as equity compensation, not through an open-market purchase, and were reported as a direct ownership acquisition.

How many Apyx Medical (APYX) RSUs were granted and at what price?

The director was granted 450,000 restricted stock units of Apyx Medical at a stated price of $0.00 per unit. This reflects a compensation award, meaning no cash was paid to acquire the units in this transaction.

What is the vesting schedule for the 450,000 Apyx Medical (APYX) RSUs?

The 450,000 RSUs vest in three tranches of 150,000 each. The first vests on June 11, 2026, the second vests ratably over twelve months starting one year later, and the third vests ratably over twelve months starting two years after the grant date.

What ongoing service conditions apply to the Apyx Medical (APYX) RSU award?

Each RSU tranche is subject to the director’s continued service through the applicable vesting dates. The award is also governed by the terms and conditions of the applicable award agreement, which can affect vesting and forfeiture outcomes.

How many Apyx Medical (APYX) shares does Stavros G. Vizirgianakis hold after this RSU grant?

After the reported RSU grant, the filing shows total direct holdings of 2,196,191 shares or share-equivalents. This figure includes the newly awarded restricted stock units as reported in the non-derivative holdings section.